Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease.


Journal

Clinical and molecular hepatology
ISSN: 2287-285X
Titre abrégé: Clin Mol Hepatol
Pays: Korea (South)
ID NLM: 101586730

Informations de publication

Date de publication:
04 2023
Historique:
received: 14 07 2022
accepted: 16 11 2022
medline: 19 4 2023
pubmed: 3 2 2023
entrez: 2 2 2023
Statut: ppublish

Résumé

Immune and inflammatory cells respond to multiple pathological hits in the development of nonalcoholic steatohepatitis (NASH) and fibrosis. Relatively little is known about how their type and function change through the non-alcoholic fatty liver disease (NAFLD) spectrum. Here we used multi-dimensional mass cytometry and a tailored bioinformatic approach to study circulating immune cells sampled from healthy individuals and people with NAFLD. Cytometry by time of flight using 36 metal-conjugated antibodies was applied to peripheral blood mononuclear cells (PBMCs) from biopsy-proven NASH fibrosis (late disease), steatosis (early disease), and healthy patients. Supervised and unsupervised analyses were used, findings confirmed, and mechanisms assessed using independent healthy and disease PBMC samples. Of 36 PBMC clusters, 21 changed between controls and disease samples. Significant differences were observed between diseases stages with changes in T cells and myeloid cells throughout disease and B cell changes in late stages. Semi-supervised gating and re-clustering showed that disease stages were associated with fewer monocytes with active signalling and more inactive NK cells; B and T cells bearing activation markers were reduced in late stages, while B cells bearing co-stimulatory molecules were increased. Functionally, disease states were associated with fewer activated mucosal-associated invariant T cells and reduced toll-like receptor-mediated cytokine production in late disease. A range of innate and adaptive immune changes begin early in NAFLD, and disease stages are associated with a functionally less active phenotype compared to controls. Further study of the immune response in NAFLD spectrum may give insight into mechanisms of disease with potential clinical application.

Sections du résumé

BACKGROUND/AIMS
Immune and inflammatory cells respond to multiple pathological hits in the development of nonalcoholic steatohepatitis (NASH) and fibrosis. Relatively little is known about how their type and function change through the non-alcoholic fatty liver disease (NAFLD) spectrum. Here we used multi-dimensional mass cytometry and a tailored bioinformatic approach to study circulating immune cells sampled from healthy individuals and people with NAFLD.
METHODS
Cytometry by time of flight using 36 metal-conjugated antibodies was applied to peripheral blood mononuclear cells (PBMCs) from biopsy-proven NASH fibrosis (late disease), steatosis (early disease), and healthy patients. Supervised and unsupervised analyses were used, findings confirmed, and mechanisms assessed using independent healthy and disease PBMC samples.
RESULTS
Of 36 PBMC clusters, 21 changed between controls and disease samples. Significant differences were observed between diseases stages with changes in T cells and myeloid cells throughout disease and B cell changes in late stages. Semi-supervised gating and re-clustering showed that disease stages were associated with fewer monocytes with active signalling and more inactive NK cells; B and T cells bearing activation markers were reduced in late stages, while B cells bearing co-stimulatory molecules were increased. Functionally, disease states were associated with fewer activated mucosal-associated invariant T cells and reduced toll-like receptor-mediated cytokine production in late disease.
CONCLUSION
A range of innate and adaptive immune changes begin early in NAFLD, and disease stages are associated with a functionally less active phenotype compared to controls. Further study of the immune response in NAFLD spectrum may give insight into mechanisms of disease with potential clinical application.

Identifiants

pubmed: 36727210
pii: cmh.2022.0205
doi: 10.3350/cmh.2022.0205
pmc: PMC10121278
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

417-432

Subventions

Organisme : Medical Research Council
ID : MR/N00308X/1
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom

Références

Hepatology. 2015 May;61(5):1547-54
pubmed: 25125077
Nature. 2021 Apr;592(7854):444-449
pubmed: 33762736
Front Immunol. 2019 Jun 04;10:1255
pubmed: 31214196
Hepatology. 2015 Jun;61(6):2067-79
pubmed: 25711908
Nature. 2019 Nov;575(7783):512-518
pubmed: 31597160
Commun Biol. 2019 May 14;2:183
pubmed: 31098416
EBioMedicine. 2022 Jan;75:103768
pubmed: 34929490
J Clin Invest. 2015 Apr;125(4):1752-62
pubmed: 25751065
Front Immunol. 2021 Feb 22;12:603133
pubmed: 33692781
PLoS One. 2016 Mar 01;11(3):e0150233
pubmed: 26930651
PLoS One. 2020 Mar 13;15(3):e0230307
pubmed: 32168345
Hepatology. 2022 May;75(5):1204-1217
pubmed: 34741554
Nat Rev Immunol. 2019 May;19(5):282-290
pubmed: 30808985
J Hepatol. 2014 May;60(5):1055-62
pubmed: 24445215
Front Immunol. 2018 Sep 04;9:1994
pubmed: 30233587
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Hepatology. 2017 May;65(5):1557-1565
pubmed: 28130788
Nat Commun. 2018 Jun 1;9(1):2146
pubmed: 29858567
Cell Mol Gastroenterol Hepatol. 2015 Nov;1(6):578-588
pubmed: 26682281
Hepatol Commun. 2018 Feb 14;2(3):285-298
pubmed: 29507903
J Immunol. 2016 Jan 1;196(1):97-105
pubmed: 26621860
Free Radic Biol Med. 2018 Aug 20;124:249-259
pubmed: 29920340
Nat Commun. 2022 Mar 31;13(1):1698
pubmed: 35361793
Front Immunol. 2021 Feb 09;11:634409
pubmed: 33633748
PLoS One. 2016 Jun 16;11(6):e0157771
pubmed: 27309850
J Rheumatol. 1999 Apr;26(4):826-32
pubmed: 10229403
Nat Metab. 2019 Jun;1(6):604-614
pubmed: 31701087
J Clin Immunol. 2011 Dec;31(6):1120-30
pubmed: 21845516
Front Immunol. 2014 Jun 03;5:258
pubmed: 24917866
Nature. 2003 Mar 13;422(6928):164-9
pubmed: 12634786
Wien Klin Wochenschr. 2018 Jun;130(11-12):390-397
pubmed: 29845362
Curr Protoc Cytom. 2010 Jul;Chapter 10:Unit10.17
pubmed: 20578106
Int J Mol Sci. 2016 Nov 10;17(11):
pubmed: 27834919
Front Immunol. 2021 Feb 18;12:640869
pubmed: 33679803
Bioinformatics. 2020 May 1;36(9):2778-2786
pubmed: 31971583
Horm Metab Res. 2016 Jan;48(1):54-61
pubmed: 25853894
Sci STKE. 2007 Sep 04;2007(402):pe48
pubmed: 17785715
Gut. 2005 Jul;54(7):987-93
pubmed: 15951547
Nat Med. 2018 Jul;24(7):908-922
pubmed: 29967350
Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):81-92
pubmed: 31605031
Cell Metab. 2013 Mar 5;17(3):411-22
pubmed: 23473035
Nat Rev Immunol. 2007 Apr;7(4):255-66
pubmed: 17380156

Auteurs

Kathryn Jane Waller (KJ)

Barts Liver Centre, Blizard Institute, Queen Mary University of London, London, UK.

Hajar Saihi (H)

Barts Liver Centre, Blizard Institute, Queen Mary University of London, London, UK.

Wenhao Li (W)

Barts Liver Centre, Blizard Institute, Queen Mary University of London, London, UK.

James Hallimond Brindley (JH)

Barts Liver Centre, Blizard Institute, Queen Mary University of London, London, UK.

Anja De Jong (A)

Barts Liver Centre, Blizard Institute, Queen Mary University of London, London, UK.

Wing-Kin Syn (WK)

Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, SC, USA.
Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country, Universidad del Pa S Vasco/Euskal Herriko Univertsitatea (UPV/EHU), Leioa, Spain.
Divisionof Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, MO, USA.

Conrad Bessant (C)

Centre for Computational Biology, Life Sciences Initiative, Queen Mary University of London, London, UK.
School of Biological and Chemical Sciences, Queen Mary University of London, London, UK.

William Alazawi (W)

Barts Liver Centre, Blizard Institute, Queen Mary University of London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH